From a new cancer-detecting device to a digital resource for childhood cancer survivors, here are some cancer-fighting innovations from Houston. Getty Images

Not all heroes wear capes. Some wear lab coats. Almost daily, it seems there's a new breakthrough or discovery for life-saving innovations.

These three cancer-related innovations are coming out of Houston, and they are ones to watch.

University of Houston's biosensor for prostate cancer reoccurrence

Dmitri Litvinov, professor of electrical and computer engineering at the University of Houston, is on a mission to bring an effective, low-cost test for prostate cancer recurrence to doctor's offices everywhere. Photo via uh.edu

Researchers from the University of Houston have teamed up with their colleagues at the University of Pennsylvania to try to get a biosensor that can detect the recurrence of prostate cancer into the doctor's office.

The research is funded by a $399,988 grant from the National Science Foundation and led by Dmitri Litvinov, principal investigator and professor of electrical and computer engineering at UH.

"Such tests exist in clinical laboratories, but there remains a critical need for inexpensive, versatile and high-sensitivity diagnostic platforms which can bring the performance to the point of care or doctor's office," says Litvinov in a release.

The biosensor platform would be less than $3 per test — an alluring fact for patients and health care providers — and would function more or less like a pregnancy test, but without a simple positive or negative response. Rather, the test can assess how much prostate-specific antigen is in a patient's blood

"Our technology has potential to help improve survival rates with more accessible, affordable and easier testing," Litvinov says.

Rice University's study that points to new cancer-fighting drug

José Onuchic co-authored a study that's opening doors for a new approach in cancer drug development. Photo by Jeff Fitlow/Rice University

A recent study in the Proceedings of the National Academy of Sciences revealed that a cancer-linked version of the protein mitoNEET can shut the gateways of mitochondria cells that supply chemical energy.

José Onuchic, a physicist and co-director of Rice University's Center for Theoretical Biological Physics, co-authored the paper and noted that the gateways, called voltage-dependent anion channels, or VDACs, typically open and shut to allow the passage of metabolites and other small molecules between mitochondria and the rest of the cell.

"The VDAC channel transports all types of metabolites between the cytosol and the mitochondria," says Onuchic in a release. "Dysfunction of this channel is involved in many diseases including cancer and fatty liver disease."

Co-author Patricia Jennings, a structural biologist at UCSD, explains in the news release.

"The discovery that mitoNEET directly gates VDAC, the major porin of mitochondria, as well as the accompanying structural analysis and predictions for this interaction, affords a new platform for investigations of methods to induce cancer cells to commit cell suicide, or apoptosis/ferroptosis, in a cancer-specific, regulated process," she writes.

The study opens doors for a new approach to cancer-treating drugs.

"Fine-tuning a drug that specifically alters the redox-state of interaction between VDAC and mitoNEET would allow the development of new weapons to battle multiple cancers," Onuchic says.

Baylor College of Medicine's digital tool for childhood cancer survivors

Baylor College of Medicine has created an online resource for childhood cancer survivors. Photo via bcm.edu

Childhood cancer survivors face a lifetime of obstacles to overcome, and Baylor College of Medicine and Texas Children's Cancer Center have developed a resource to help these patients have the best quality of life in remission.

Passport for Care, a free online resource, features a "survivorship care plan" for the patient, his or her doctor, and family members. The program's new Screenings Recommendations Generator tool can provide a childhood cancer survivor with potential late effects and how to manage their care.

"This tool is especially helpful for patients who have moved on to other doctors who they did not see as a child and who might not be familiar with their particular treatment and the subsequent health risks," says Dr. David Poplack, founder of the Passport for Care and associate director of the Texas Children's Cancer and Hematology Centers, in a news release. "It helps physicians understand their patient's history and know how to address future health problems."

Over 37,000 cancer survivors are using Passport for Care at 138 clinics around the world. Additionally, patients can also register through the Screenings Recommendations Generator.

Passport for Care is funded by the Cancer Prevention & Research Institute of Texas, as well as through a grant from Hyundai Hope on Wheels.

"We created Passport for Care with the goal of empowering survivors in their healthcare decisions," Poplack says. "Their care doesn't end when cancer treatment is over. Survivorship care is a lifelong journey."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”